AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE SPECIFICATION

Please amend the specification, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows (and as shown in the accompanying Appendix: Marked-Up Version To Show Changes Made):

Page 1, in the text added by the December 12, 2000 Preliminary Amendment, please delete:

"STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

Not applicable."

Page 3, please rewrite the fourth full paragraph (the text after line 14 and before line 20), as follows:

--The subject of the present invention is plasmid constructs encoding and expressing a PCV-1 or PCV-2 immunogen, in particular the open reading frames (ORFs) 1 and/or 2 for PCV-1, and the ORFs 1 and/or 2 for PVC-2 (ORF means Open Reading Frame).--

Page 7, please rewrite the first paragraph under the formula (beginning with "in") as follows:

--in which R_1 is a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, R_2 is another aliphatic radical comprising from 2 to 3 carbon atoms, and X is a hydroxyl or amine group.--

Pages 21-22, please rewrite the paragraph that spans these pages as follows:

-- Groups of 3 or 4 piglets, caesarian-derived day 0 are placed into isolators. The piglets are vaccinated day 2 either with pJP109 alone or with pJP109 and pJP111 plasmids mixture and with a physiological solution for the control group. Each plasmid is diluted in sterile physiological solution (NaCl 0,9%) at 250 μg/ml final concentration. A 2 ml volume is injected by intramuscular route in two points of 1 ml (1 point each side of the neck). A second injection of vaccine or placebo is administered day 14. Vaccination with DNA is well tolerated by piglets and no evidence for adverse reaction to vaccination is noted. The piglets are challenged day 21 by oronasal administration of PCV-2 viral suspension, 1 ml in each nostril. After challenge